European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading

MT Newswires Live
07/07

European equities traded in the US as American depositary receipts started the week modestly lower late Monday morning, declining 0.26% to 1,486.79 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by internet advertising firm Criteo (CRTO) and biopharmaceutical company Cellectis (CLLS), which rose 1.5% and 1.3%, respectively. They were followed by software firm SAP (SAP) and telecommunications company Ericsson (ERIC), which were up 0.9% and 0.8%, respectively.

The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and biotech firm Evaxion (EVAX), which fell 5.5% and 4.4%, respectively. They were followed by accommodations booking company trivago (TRVG) and semiconductor company Sequans Communications (SQNS), which lost 3.8% and 3.4%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company Mereo BioPharma Group (MREO) and pharmaceutical company Silence Therapeutics (SLN), which advanced 5.1% and 2.4%, respectively. They were followed by telecommunications operator Vodafone Group (VOD) and financial services company HSBC (HSBC), which increased 1.8% and 0.9%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Bicycle Therapeutics (BCYC) and NuCana (NCNA), which dropped 4.3% and 2.6%, respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and oil and gas company Shell (SHEL), which were down 2.5% and 2.1%, respectively.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10